# AGENDA

**Monday, September 11, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td>BREAKFAST AVAILABLE</td>
</tr>
</tbody>
</table>
| 7:30 a.m.| Welcome to Heart House
Richard J. Kovacs, MD, FACC; Chair, Science and Quality Committee |
| 7:40 a.m.| Opening Remarks and Introductions
Christie M. Ballantyne, MD, FACC, FACP, FNLA; Chair, LDL: Address the Risk Think Tank |
| 7:55 a.m.| Falling Short of the Finish Line for the High-Risk Patient: Barriers to Implementation of Evidence-based Guidelines
Salim S. Virani, MD, PhD, FACC, FAHA |
| 8:10 a.m.| **SESSION 1: DIAGNOSTIC, RISK ASSESSMENT, AND MANAGEMENT DILEMMA IN PATIENTS WITH VERY HIGH LDL-C (≥ 190 MG/DL)**
- Patient Cases Allison Dimsdale, DNP, NP-C, AACC, FAANP (5 minutes)
- Distinguishing FH from non-FH: Right Therapy, Right Patient, Right Time
  Joshua W. Knowles, MD, PhD (10 minutes)
- When is ASCVD Risk Based On More than Just a Number?
  P. Barton Duell, MD (10 minutes)
- Interactive Table Discussion (60 minutes)
- Report Back to Full Group (35 minutes) |
| 10:10 a.m.| BREAK |
| 10:30 a.m.| **SESSION 2: NOT SO BLACK AND WHITE: RISK ASSESSMENT AND MANAGEMENT IN PATIENTS WITH DIABETES**
- Patient Cases Allison Dimsdale, DNP, NP-C, AACC, FAANP (5 minutes)
- CV Risk Assessment in Patients with Diabetes: What Event, Which Tool, What Test?
  Christie M. Ballantyne, MD, FACC, FACP, FNLA (10 minutes)
- When Statins Aren’t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
  Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS (10 minutes)
- Interactive Table Discussion (60 minutes)
- Report Back to Full Group (35 minutes) |
| 12:30 p.m.| LUNCH |
| 1:30 p.m.| **SESSION 3: AVOIDING AN ENCORE PERFORMANCE: PREVENTION IN THE PATIENT WITH CLINICAL ASCVD**
- Patient Cases Allison Dimsdale, DNP, NP-C, AACC, FAANP (5 minutes)
- A Risky Game of Jeopardy: Optimizing Statin Therapy is the Correct Answer
  Salim S. Virani, MD, PhD, FACC, FAHA (10 minutes)
- Utilizing Quantitative Data to Optimize Benefits of Non-Statin Therapies in Patients with ASCVD
  Jennifer Robinson, MD, MPH (10 minutes)
- Coming to Consensus in the New Era: 2017 Focused Update of the 2016 ECDP on Non-Statin Therapies
  Pamela B. Morris, MD, FACC, FACP, FACP-M, FAHA, FNLA (10 minutes)
- Interactive Table Discussion (55 minutes)
- Report Back to Full Group (30 minutes) |
| 3:30 p.m.| Recap of the Day and Next Steps
Christie M. Ballantyne, MD, FACC, FACP, FNLA |
| 4:00 p.m.| ADJOURN |